We are pleased to announce our latest news to you.
Claudia and Ilona Brandt are twin sisters. They are SMA (spinal muscular atrophy) patients and founders of the SMArty-Symposium in Germany. Through their disease, they regularly observe unmet needs and optimization potentials for their medical aids and other treatment and care related technologies.
admedicum and HollandBIO presented the Patient Engagement Guide (PEG) at this year’s Dutch Biotech Event on June 29 in Utrecht, NL.
admedicum recently moderated another pharma-patient forum about "Patient Engagement in pharmaceutical R&D“. Our client, a pharmaceutical company, invited advocates from a number of German patient groups, both for common and rare diseases. Joint working groups facilitated an exchange mainly on expectations, suggestions, and concerns on behalf of the patient advocates with regard to collaboration with the company.
We are delighted to announce that admedicum has the honor to call Maryze Schoneveld van der Linde a new Strategic Partner! Maryze, is a rare disease advocate and expert by experience regarding drug development, active patient involvement from the patient perspective, empowerment related issues and building networks. Maryze is a Pompe patient bound to wheelchair and thus has been advocating the actual real life experience of patients at many international conferences, events and company patient engagement initiatives.
We are delighted to announce that admedicum has today welcomed a new Associate Partner to its team. Rachel Jones who is UK based, is former global Global Patient Centricity Lead at Astra Zeneca and experienced Patient Engagement Expert. She is a welcome member of our growing International consultancy team which aims to connect Pharmaceutical companies with patients in order to deliver the best solutions for all. Rachel has over a decades ...
Search the news
We gladly answer your questions concerning the contribution of admedicum® at the below mentioned events. Registration shall be submitted via the concerned organizers exclusively.